Merrimack continues its slide; sets another new 52-week low

Shares in Merrimack Pharmaceuticals (MACK -4.2%) move lower again today to set a new 52-week low once again.

Initially, the stock spiked more than 26% higher in the pre-market, possibly helped by a positive Seeking Alpha blog.

The SA contributor notes that MM-121, a therapeutic antibody for treating tumors, is the key drug in its portfolio. The company expects three trials involving MM-121 to report in late 2013.

If positive, I this could lead to a substantial revaluing of the company, and potentially an acquisition by a larger drug company.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs